Matches in SemOpenAlex for { <https://semopenalex.org/work/W2032946274> ?p ?o ?g. }
- W2032946274 endingPage "476" @default.
- W2032946274 startingPage "468" @default.
- W2032946274 abstract "To determine the efficacy and safety of cyclical etidronate for up to 7 years in the treatment of postmenopausal osteoporosis and to examine the effects of discontinuing treatment after 2 or 5 years of therapy.Patients were randomized at entry into the original study in 1986 to blinded treatment for 2 years with either a calcium (placebo) or an intermittent cyclical etidronate regimen, which most patients continued for a third year. Following this phase of the study, patients were enrolled into an open-label, follow-up study (years 4 and 5), during which all patients received cyclical etidronate treatment. In the present double-blind study (years 6 and 7), patients were rerandomized to receive intermittent cyclical therapy with either etidronate or placebo; all patients received calcium. The treatment regimen consisted of 400 mg/day etidronate or placebo for 14 days, followed by 76 days of elemental calcium (500 mg/day); this cycle was repeated approximately 4 times in each year. Of the 193 patients who continued in years 6 and 7 of the study, 93 were randomized to receive cyclical etidronate and 100 were randomized to receive calcium only. For purposes of efficacy analyses, patients were categorized by their total years of cumulative etidronate treatment (7, 5, 4, or 2 years). There were 51, 46, 42, and 54 patients in the 7-, 5-, 4-, and 2-year groups, respectively. Annual assessments included lumbar spine bone mineral density (BMD), as measured by densitometry, and vertebral radiographs.The groups receiving cyclical etidronate during this 2-year study period (7- and 4-year groups) had statistically significant mean percent increases in spinal BMD of 1.8% and 2.2%, respectively (P < 0.05) at the week 104 observation time. The 5- and 2-year groups, which did not receive etidronate during this period, had mean values of 1.4% and 0.2%, respectively (not significant) at week 104. In the 7-, 5-, 4-, and 2-year groups, the increases in spinal BMD at the end of 7 years were 7.6%, 8.6%, 8.1%, and 3.9%, respectively; these values were statistically significant for all groups compared with original baseline (year 0) (P < 0.05). BMD of the femur and wrist was maintained throughout the 7-year period. The incidence and rate of vertebral fractures were lowest in patients with the longest exposure to etidronate. Etidronate was well tolerated during the study, with low incidences of gastrointestinal side effects and nonvertebral fractures.Long-term cyclical etidronate is a safe, effective, and well-tolerated treatment for postmenopausal osteoporosis. Bone mass is maintained for at least 2 years after treatment with etidronate is stopped; however, further gains in spinal bone mass are seen in patients who continue therapy." @default.
- W2032946274 created "2016-06-24" @default.
- W2032946274 creator A5003671346 @default.
- W2032946274 creator A5008975841 @default.
- W2032946274 creator A5019562480 @default.
- W2032946274 creator A5027234402 @default.
- W2032946274 creator A5030361963 @default.
- W2032946274 creator A5031463205 @default.
- W2032946274 creator A5042012204 @default.
- W2032946274 creator A5047122819 @default.
- W2032946274 creator A5052103282 @default.
- W2032946274 creator A5056543763 @default.
- W2032946274 creator A5062804698 @default.
- W2032946274 creator A5090665248 @default.
- W2032946274 date "1997-12-01" @default.
- W2032946274 modified "2023-09-30" @default.
- W2032946274 title "Cyclical Etidronate in the Treatment of Postmenopausal Osteoporosis" @default.
- W2032946274 cites W115187101 @default.
- W2032946274 cites W1968418396 @default.
- W2032946274 cites W1978920283 @default.
- W2032946274 cites W1997724539 @default.
- W2032946274 cites W2007835049 @default.
- W2032946274 cites W2044178924 @default.
- W2032946274 cites W2062229770 @default.
- W2032946274 cites W2063006320 @default.
- W2032946274 cites W2065399719 @default.
- W2032946274 cites W2075080805 @default.
- W2032946274 cites W2087378917 @default.
- W2032946274 cites W2090642025 @default.
- W2032946274 cites W2091737798 @default.
- W2032946274 cites W2130415005 @default.
- W2032946274 cites W2151649765 @default.
- W2032946274 cites W2153009489 @default.
- W2032946274 cites W2155728216 @default.
- W2032946274 cites W2321227665 @default.
- W2032946274 cites W2325302070 @default.
- W2032946274 cites W2336517627 @default.
- W2032946274 cites W2336678594 @default.
- W2032946274 doi "https://doi.org/10.1016/s0002-9343(97)00278-7" @default.
- W2032946274 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9428829" @default.
- W2032946274 hasPublicationYear "1997" @default.
- W2032946274 type Work @default.
- W2032946274 sameAs 2032946274 @default.
- W2032946274 citedByCount "149" @default.
- W2032946274 countsByYear W20329462742013 @default.
- W2032946274 countsByYear W20329462742016 @default.
- W2032946274 countsByYear W20329462742019 @default.
- W2032946274 countsByYear W20329462742020 @default.
- W2032946274 countsByYear W20329462742021 @default.
- W2032946274 countsByYear W20329462742022 @default.
- W2032946274 countsByYear W20329462742023 @default.
- W2032946274 crossrefType "journal-article" @default.
- W2032946274 hasAuthorship W2032946274A5003671346 @default.
- W2032946274 hasAuthorship W2032946274A5008975841 @default.
- W2032946274 hasAuthorship W2032946274A5019562480 @default.
- W2032946274 hasAuthorship W2032946274A5027234402 @default.
- W2032946274 hasAuthorship W2032946274A5030361963 @default.
- W2032946274 hasAuthorship W2032946274A5031463205 @default.
- W2032946274 hasAuthorship W2032946274A5042012204 @default.
- W2032946274 hasAuthorship W2032946274A5047122819 @default.
- W2032946274 hasAuthorship W2032946274A5052103282 @default.
- W2032946274 hasAuthorship W2032946274A5056543763 @default.
- W2032946274 hasAuthorship W2032946274A5062804698 @default.
- W2032946274 hasAuthorship W2032946274A5090665248 @default.
- W2032946274 hasConcept C126322002 @default.
- W2032946274 hasConcept C141071460 @default.
- W2032946274 hasConcept C142724271 @default.
- W2032946274 hasConcept C168563851 @default.
- W2032946274 hasConcept C204787440 @default.
- W2032946274 hasConcept C27081682 @default.
- W2032946274 hasConcept C2776541429 @default.
- W2032946274 hasConcept C2776886416 @default.
- W2032946274 hasConcept C2781104859 @default.
- W2032946274 hasConcept C2781413609 @default.
- W2032946274 hasConcept C71924100 @default.
- W2032946274 hasConceptScore W2032946274C126322002 @default.
- W2032946274 hasConceptScore W2032946274C141071460 @default.
- W2032946274 hasConceptScore W2032946274C142724271 @default.
- W2032946274 hasConceptScore W2032946274C168563851 @default.
- W2032946274 hasConceptScore W2032946274C204787440 @default.
- W2032946274 hasConceptScore W2032946274C27081682 @default.
- W2032946274 hasConceptScore W2032946274C2776541429 @default.
- W2032946274 hasConceptScore W2032946274C2776886416 @default.
- W2032946274 hasConceptScore W2032946274C2781104859 @default.
- W2032946274 hasConceptScore W2032946274C2781413609 @default.
- W2032946274 hasConceptScore W2032946274C71924100 @default.
- W2032946274 hasIssue "6" @default.
- W2032946274 hasLocation W20329462741 @default.
- W2032946274 hasLocation W20329462742 @default.
- W2032946274 hasOpenAccess W2032946274 @default.
- W2032946274 hasPrimaryLocation W20329462741 @default.
- W2032946274 hasRelatedWork W2003938723 @default.
- W2032946274 hasRelatedWork W2047967234 @default.
- W2032946274 hasRelatedWork W2117797268 @default.
- W2032946274 hasRelatedWork W2118496982 @default.
- W2032946274 hasRelatedWork W2362391313 @default.
- W2032946274 hasRelatedWork W2384946314 @default.
- W2032946274 hasRelatedWork W2439875401 @default.